Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Current Leases (2019 - 2025)

Integra Lifesciences Holdings' Current Leases history spans 7 years, with the latest figure at $14.0 million for Q4 2025.

  • For Q4 2025, Current Leases changed N/A year-over-year to $14.0 million; the TTM value through Dec 2025 reached $14.0 million, changed N/A, while the annual FY2025 figure was $14.0 million, N/A changed from the prior year.
  • Current Leases for Q4 2025 was $14.0 million at Integra Lifesciences Holdings, up from $13.8 million in the prior quarter.
  • Across five years, Current Leases topped out at $16.3 million in Q1 2024 and bottomed at $13.5 million in Q3 2021.
  • The 5-year median for Current Leases is $14.6 million (2024), against an average of $14.5 million.
  • The largest annual shift saw Current Leases grew 15.27% in 2021 before it decreased 2.99% in 2025.
  • A 5-year view of Current Leases shows it stood at $14.8 million in 2021, then dropped by 1.02% to $14.6 million in 2022, then increased by 4.51% to $15.3 million in 2023, then decreased by 4.39% to $14.6 million in 2024, then fell by 4.06% to $14.0 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Current Leases are $14.0 million (Q4 2025), $13.8 million (Q3 2025), and $14.2 million (Q2 2025).